Following in Banting's footsteps or straying from the path? Observations from contemporary diabetes innovation.
conference
diabetes technology
equity
type 1 diabetes
type 2 diabetes
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2023
2023
Historique:
received:
31
07
2023
accepted:
20
10
2023
medline:
4
12
2023
pubmed:
30
11
2023
entrez:
30
11
2023
Statut:
epublish
Résumé
While advancements in the treatment of diabetes continue to rapidly evolve, many of the newer technologies have financial barriers to care, opposing the egalitarian ethos of Banting who sold his patent on insulin for a nominal cost to allow it to be made widely available. Inequity in access to new therapies drives disparity in diabetes burden with potential for these gaps to widen in the future. The 2023 International Conference on Advanced Technologies and Treatments of Diabetes (ATTD) presented ground-breaking and current research in diabetes technology. Oral presentations of the ATTD conference 2023 were analyzed to describe what percentage of speakers discussed equity in their talks. Overall, less than a quarter of presenters discussed equity, though there was regional variation. To ensure that diabetes technologies reduce disparity and improve outcomes, we encourage future speakers at diabetes (technology) conferences to consider equity of diabetes care and incorporate this into their presentations.
Identifiants
pubmed: 38033993
doi: 10.3389/fendo.2023.1270517
pmc: PMC10686253
doi:
Substances chimiques
Insulin
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1270517Informations de copyright
Copyright © 2023 Leadley, Addala, Berkeley, Crocket, Davis, Hewapathirana, Hussain, Lal, Lomax, Wilkinson, de Bock and Burckhardt.
Déclaration de conflit d'intérêts
MD declares receiving speaker fees from Medtronic, Dexcom, Boerhinger Ingelheim, research support from Dexcom, Medtronic, Novonordisk, Pfizer, SOOIL, and has served as advisory board membership for Dexcom. RL receives consulting fees from Abbott DIabetes Care, Gluroo, PhysioLogic Devices, Provention Bio and is chief medical advisor for Tidepool. He receives research support from NIDDK 1K23DK122017 and P30 DK116074, JDRF, Abbott, Insulet, Medtronic and Tandem. ED declares receiving speaker fees from Lilly, and being part of speaker’s bureau for Dexcom. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Diabetes Care. 2021 Jan;44(1):133-140
pubmed: 32938745
J Clin Endocrinol Metab. 2020 Aug 1;105(8):
pubmed: 32382736
Acta Diabetol. 2017 Jan;54(1):63-71
pubmed: 27650535
Diabetes Care. 2021 Jan;44(1):14-16
pubmed: 33444165
Lancet Reg Health West Pac. 2022 Nov 17;31:100644
pubmed: 36419466
Diabetes Spectr. 2022 Summer;35(3):266-275
pubmed: 36082008
Int J Health Serv. 2011;41(2):231-8
pubmed: 21563622